Skip to main content

Clinical Trials

IDEAYA is dedicated to pioneering oncology treatments through innovative clinical trials. Through rigorous scientific inquiry and unwavering dedication, we strive to bring new hope to cancer patients and contribute to the advancement of oncology treatment paradigms. Our clinical trials page offers a comprehensive overview of our ongoing studies which span various solid tumor cancer types, with a focus on biomarker-driven approaches.

Darovasertib
PKC

Darovasertib PKC

IDE196-002

Metastatic Uveal Melanoma

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotinib or investigator’s choice of treatment (pembrolizumab, ipilimumab + nivolumab, or dacarbazine).

Recruiting

18 Years and older (Adult, Older Adult)
All Sexes

NCT ID: 5987332

Learn More

IDE196-001

Patients with Solid Tumors Harboring GNAQ/11 Mutations

Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations, including metastatic uveal melanoma (MUM) and cutaneous melanoma

Recruiting

18 Years and older (Adult, Older Adult)
All Sexes

NCT ID: 03947385

Learn More

IDE196-009

Uveal Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Recruiting

18 Years and older (Adult, Older Adult)
All Sexes

NCT ID: 05907954

Learn More

IDE397
MAT2A

IDE397 / MAT2A

IDE397-001

Solid Tumors Harboring MTAP Deletion

This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and anti-tumor activity of IDE397 as a single agent and in combination with docetaxel or paclitaxel, or sacituzumab govitecan-hziyin (SG)  in adult patients with selected advanced or metastatic MTAP-deleted advanced solid tumors who are unresponsive to standard of care therapy or for whom no curative therapy is available. IDE397 is a small molecule inhibitor of methionine adenosyltransferase 2 alpha (MAT2A).

Recruiting

18 Years and older (Adult, Older Adult)
All Sexes

NCT ID: 04794699

Learn More

IDE161
PARG

IDE161 / PARG

IDE161-001

Patients with HRD Mutations

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Recruiting

18 Years and older (Adult, Older Adult)
All Sexes

NCT ID: 05787587

Learn More

Disclaimer: This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.

Expanded Access Policy

Investigational drugs are medical products that have not yet been approved or cleared by FDA and the FDA has not found these drug products to be safe and effective for their specific use. Investigational drug products may, or may not, be effective in the treatment of the condition for which they are being investigated, and use of the product may cause unexpected serious side effects.

Currently, participation in a clinical trial is the only way to receive any of IDEAYA’s investigational drugs. Until further safety and efficacy data become available, we will not be making these investigational drugs available in other ways. If you have questions about participating in a clinical trial, please speak to your treating physician or contact IDEAYAClinicalTrials@ideayabio.com.

Contact Us About a Trial

Complete the Form to Inquire About Clinical Trials
Fill out my online form.
CONTACT US

5000 Shoreline Court, Suite 300
South San Francisco, CA 94080

11710 El Camino Real
San Diego, CA 92130